Open Access

Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway

  • Authors:
    • Fang‑Fang Chen
    • Xing Lv
    • Qin‑Fei Zhao
    • Yu‑Zhong Xu
    • Shu‑Sheng Song
    • Wei Yu
    • Xiao‑Jun Li
  • View Affiliations

  • Published online on: May 31, 2018     https://doi.org/10.3892/ol.2018.8849
  • Pages: 1634-1640
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Inhibitor of DNA‑binding 3 (ID3) is a helix‑­loop‑helix transcription factor that is associated with cell proliferation, differentiation and drug resistance in human cancer, and with anticancer effects in certain types of cancer cells. The present study investigated whether and how ID3 was involved in multidrug resistance (MDR) in human cisplatin (DDP)‑resistant A549/DDP lung adenocarcinoma cells. The underlying mechanism of action was investigated in vitro. Cell Counting Kit‑8 (CCK‑8) and flow cytometry assays demonstrated that overexpression of ID3 enhanced chemosensitivity and decreased drug efflux in A549/DDP cells. Reverse transcription‑quantitative polymerase chain reaction revealed that the expression of anti‑apoptotic gene B‑cell lymphoma‑2 was significantly downregulated in cells expressing exogenous ID3 (P<0.05). These results indicated that ID3 may synergize with DDP to increase apoptosis in A549/DDP cells. ID3 overexpression modulated the activity of phosphoinositide 3‑kinase/RAC serine/threonine‑protein kinase signaling and downregulated the expression of multi‑drug resistance protein‑1, indicating that ID3 expression can reverse multi‑drug resistance in A549/DDP cells. Collectively, these results indicate that ID3 is a potential effective chemotherapeutic target for the treatment of human DDP‑resistant A549 lung adenocarcinoma therapy.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 16 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen FF, Lv X, Zhao QF, Xu YZ, Song SS, Yu W and Li XJ: Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway. Oncol Lett 16: 1634-1640, 2018
APA
Chen, F., Lv, X., Zhao, Q., Xu, Y., Song, S., Yu, W., & Li, X. (2018). Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway. Oncology Letters, 16, 1634-1640. https://doi.org/10.3892/ol.2018.8849
MLA
Chen, F., Lv, X., Zhao, Q., Xu, Y., Song, S., Yu, W., Li, X."Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway". Oncology Letters 16.2 (2018): 1634-1640.
Chicago
Chen, F., Lv, X., Zhao, Q., Xu, Y., Song, S., Yu, W., Li, X."Inhibitor of DNA binding 3 reverses cisplatin resistance in human lung adenocarcinoma cells by regulating the PI3K/Akt pathway". Oncology Letters 16, no. 2 (2018): 1634-1640. https://doi.org/10.3892/ol.2018.8849